Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group, publicly listed in Japan (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK).

Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected technology and platform.

Our primary focus is the discovery and early development of new medicines originating from its proprietary G Protein-Coupled Receptor (GPCR)-targeted StaR® technology and Structure-Based Drug Design (SBDD) platform capabilities. The company is advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.

The company has established partnerships with some of the world’s leading pharmaceutical companies, including Allergan, AstraZeneca, Daiichi-Sankyo, Genentech (Roche), Novartis, Pfizer and Takeda; and with innovative biotechnology companies, including Kymab, MorphoSys and PeptiDream.

Sosei Heptares has approximately 145 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.

As part of the newly formed Preclinical Development Group, bringing integrated drug development focus on the portfolio, the role will bring chemistry and pharmaceutical sciences expertise to Drug Substance Design requirements throughout the project lifecycle in drug development. The role will progress multiple projects in preclinical and clinical development over several therapeutic areas in the portfolio.  Key responsibilities include:

• Manage and provide scientific problem-solving contributions to the Drug Substance Design and CMC specialism across late stage lead optimisation, preclinical and clinical projects at Sosei Heptares, to agreed regulatory standard, timelines and budget.
• Author, review and support CMC section of regulatory documentation.
• Be an active member of Sosei Heptares project teams.
• Work closely with and get expert input from scientists within Sosei Heptares, consultants  and specialist vendors to meet the Company's objectives.

The successful candidate is expected to have:

• Minimum of BSc in synthetic organic chemistry (or related discipline) with at least 5 years’ experience in drug substance CMC.
• In depth understanding of relevant GMP requirements for manufacture of drug substance for use in clinical trials
• In depth understanding of relevant regulatory requirements for manufacture of drug substance for use in clinical trials.
• Excellent project management skills with ability to multitask on multiple projects at any given time

This position is amenable to flexible working arrangements including working from home. We are happy to discuss what works best for individual circumstances.

Applicants must be able to demonstrate proof of the right to work in the United Kingdom.

We offer a competitive salary and benefits package commensurate with qualifications and experience.

Sosei Heptares is an equal opportunities employer.

Applications should include a covering letter and curriculum vitae. Please apply for this post via our on-line recruitment portal. Please attach your application in pdf format, quoting reference number 2020/2D. The closing date for applications is 26th June 2020.

Strictly no agencies.